Stryker won FDA pre-market approval for its Surpass Streamline Flow Diverter, a device indicated for treatment of large and even giant unruptured intracranial aneurysms. This is only the second flow diverting stent to be approved in the U.S., the first being from Medtronic.
“Surpass Streamline is the first flow diverter indicated for large and giant posterior communicating artery aneurysms. These unruptured aneurysms are more challenging due to their location and surrounding anatomy. Having Surpass approved for this and other locations is an important advantage for physicians and patients,” in a published statement said Dr. Philip Meyers, Professor of Radiology and Neurological Surgery at New York Presbyterian/Columbia University Medical Center and Co-Principal Investigator for the SCENT trial which led to the latest approval. “The stent is designed to reliably open and provide consistent mesh density across the neck of the aneurysm to aid in aneurysm occlusion while maintaining perforator artery patency.”
The stent is made of cobalt chromium and it’s positioned so that it runs next to the aneurysm being treated. Blood passing through the section containing the stent eventually doesn’t penetrate into the aneurysm and therefore helps to prevent rupture and its potentially catastrophic consequences.
Product page: Surpass Streamline Flow Diverter…
Via: Stryker…
